Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer Liver Metastases (CRLM)
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)
This multicenter, retrospective study aims to develop and validate a multimodal deep learning model for predicting the risk of metachronous liver metastasis in patients with stage I-III colorectal cancer following curative…
- Trial name
- NCT07399236
- Testing
- Multimodal Deep Learning Model Analysis
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tongji Hospital
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer.
- Conditions
- EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT03087071
- Testing
- Laboratory Biomarker Analysis, Panitumumab, Trametinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Colonic Neoplasms
Enzastaurin for Patients With Metastatic Colorectal Cancer
Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer
- Trial name
- NCT00192114
- Testing
- Enzastaurin HCl
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Colorectal Cancer Metastatic
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer
- Trial name
- BLOOMSI (NCT06414304)
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- OncoAtlas LLC
Ovarian Neoplasms, Colorectal Neoplasms
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy.
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer
- Trial name
- NCT00132704
- Testing
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oligometastatic Disease
Prediction of True Oligo-metastatic Disease.
In recent years, the scientific community has recognized the need to differentiate between poly- and oligo-metastatic disease (OMD) in oncology due to their distinct clinical and biological behavior.
- Trial name
- PREDICTION (NCT05806151)
- Testing
- Genetic and immunologic assessments
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute, Naples
Colo-rectal Cancer
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal…
- Trial name
- NCT06011772
- Testing
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients. Oral irinotecan will be administered as monotherapy in a dose escalation trial to establish the Maximal…
- Trial name
- NCT03295084
- Testing
- Irinotecan, Capecitabine
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Dorte Nielsen
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Neoplasms, Colonic Neoplasms
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00056459
- Testing
- Vatalanib
- Where
- 223 sites in United States, Australia and 17 more
- Volunteers
- 1,168 people
- Sponsor
- Novartis
Recurrent Colorectal Cancer
A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
The study evaluates the effectiveness of radiotherapy combined with raltitrexed and irinotecan in treating patients who have metastatic or locally recurrent colorectal cancer that has not responded to fluorouracil.
- Trial name
- NCT04499586
- Testing
- Radiotherapy Combined With Raltitrexed and Irinotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Colon Cancer, Immunotherapy
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab
- Trial name
- NCT06573424
- Testing
- Tislelizumab+anlotinib, anlotinib
- Where
- China
- Volunteers
- 124 people
- Sponsor
- fan li
Metastatic Colorectal Cancer
PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer
The primary objective of the two phase PERMAD trial is the evaluation of the impact of a personalized marker-driven treatment approach with early detection of progression and modification of treatment on cytokines and angiogenic…
- Trial name
- PERMAD (NCT02331927)
- Testing
- Aflibercept
- Where
- 3 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Ulm
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
- Trial name
- BOND-4 (NCT07722754)
- Testing
- Cetuximab, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Neoplasms
Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
(1) Evaluate the efficacy of apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer. Whether it can prolong Progression Free Survival (PFS), overall survival (OS) in patients with advanced…
- Trial name
- NCT03412994
- Testing
- Apatinib, standard second-line chemotherapy
- Volunteers
- 60 people
- Sponsor
- Liqiang Zhong
Unresectable/Metastatic Colorectal Cancer
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
FOLFOXIRI-based regimen is more used as a first-line therapeutic approach for patients diagnosed with unresectable or metastatic colorectal cancer for its superior efficacy.
- Trial name
- NCT06148402
- Testing
- Fruquintinib plus camrelizumab and capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Phase II - Treatment Regimen Exploration Stage: 1. Evaluate the safety and efficacy of the following three treatment regimens: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV +…
- Conditions
- Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
- Trial name
- NCT07585279
- Testing
- Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Hebei Medical University Fourth Hospital
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II
Effect of Hemp-CBD on Patients With CIPN
The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer
- Trial name
- Coala-T-CBD (NCT04398446)
- Testing
- Hemp-based CBD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Main Line Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.